Start Your Morning With a Cup of Coffee and an Ounce of Dengue Prevention
SINGAPORE, June 15, 2017 /PRNewswire/ --
Sanofi Pasteur
Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China
SHANGHAI, Dec. 5, 2016 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities inWuhan and Taiwan, announced today a strategic alliance to collaborate on the develo...
Sanofi's Toujeo(R) Demonstrated a Consistently Lower Rate of Hypoglycemia Compared to Lantus(R) at All Levels of HbA1c control
PARIS, Sept. 13, 2016 /PRNewswire/ --
- Benefits on adherence and HbA1c to be validated in a real-world setting -
Sanofi
Dengue Immunization Public Program in Parana State of Brazil Set To Achieve WHO 2020 Ambition
- First dengue immunization public program in the Americas starts today targeting broad age range of individuals at highest risk of disease consistent with recent WHO position - Parana state will lead Dengue prevention in Brazil launching benchmark public program to immunize 500,000 individuals ...
Sanofi Pasteur Dengue Vaccine Approved in Costa Rica
SAN JOSE, Costa Rica, June 23, 2016 /PRNewswire/ -- Today Sanofi Pasteur, Sanofi's vaccine division, announced that the National Ministry of Health ofCosta Rica has approved Sanofi Pasteur's tetravalent dengue vaccine, Dengvaxia®, to protect individuals 9 to 45 years of age living in endemic area...
ADVA launches Dengue Mission Buzz Barometer tool to boost critical dengue prevention awareness and preparedness amongst ASEAN Community
SINGAPORE, June 15, 2016 /PRNewswire/ -- In support of the 6th Association of Southeast Asian Nations (ASEAN) Dengue Day, the Asian Dengue Vaccination Advocacy (ADVA) is launching the Dengue Mission Buzz Barometer, a tool to measure ASEAN community engagement for the prevention of dengue. The Bar...
Strategic Advisory Group of Experts on Immunization Convened by the World Health Organization Recommends Use of Sanofi Pasteur's Dengue Vaccine in Endemic Countries
SINGAPORE, April 15, 2016 /PRNewswire/ --Sanofi
First Dengue Vaccine, Dengvaxia(R), Awarded 'The Vaccine Breakthrough of 2016' At the 6th Annual Biopharma Industry Awards Event In Singapore
SINGAPORE, March 28, 2016 /PRNewswire/ -- Sanofi Pasteur
Sanofi Pasteur's Dengue Vaccine Approved in the Philippines
LYON, France, Dec. 22, 2015 /PRNewswire/ -- Sanofi Pasteur
TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with Better Quality of Life for Young People with Type 1 Diabetes
PARIS, June 17, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the first results of the TEENs Registry Study, the largest contemporary real-world study of the care of nearly 6,000 young people with type 1 diabetes, ages 8 to 25. The findings not only highlighted that over ...
Sanofi's Lyxumia(R) (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine
PARIS, June 17, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar)...
Sanofi to Present New Clinical Data at American Diabetes Association 74th Scientific Sessions
-- New results for Toujeo(R) (insulin glargine [rDNA origin] injection, 300 U/mL; "U300") from EDITION I/II/III meta-analysis, EDITION III, IV, JP 1 and JP 2 studies are among over 65 abstracts to be presented PARIS, June 11, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced tod...
New Data Support Flexibility in Timing of Administration for Sanofi's Lyxumia(R)
PARIS, Dec. 5, 2013 /PRNewswire/ -- - Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the results of a 24-week Phase IIIb clinical study showing that Lyxumia(R) (lixisenatide) met the p...
Lyxumia(R) is First Diabetes Therapy of its Class Approved in Japan for use in Combination with Basal Insulin
PARIS, June 28, 2013 /PRNewswire/ -- - First once-daily prandial GLP-1 receptor agonist offering a new treatment option for Japanese people living with type 2 diabetes - Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approv...
Patient-led Titration with Lantus(R) is Effective at Lowering Blood Glucose
- Self-empowerment for titration showed to be effective in ATLAS while education helps managing the slightly increased hypoglycemia risk in patient-led study arm - PARIS, France, June 24, 2013 /PRNewswire/ -- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today data from the Asian Treat to Targ...
